Nature`s Sunshine Products's EBIT is $21M, below the Healthcare sector average of $1.9T.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
As of the most recent data (September 2026), NATR shows a EBIT of $21M. That compares with $13M in the prior-year period — up 61.3% year over year. That is below the Healthcare sector average of $1.9T. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, NATR's EBIT is now $21M (was $13M) — a 61.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Nature`s Sunshine Products is outperforming or lagging.
The Healthcare sector average EBIT is about $1.9T. Nature`s Sunshine Products is at $21M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how NATR stacks up against individual peers as well.
Tracking NATR's ebit over time shows whether Nature`s Sunshine Products is scaling, shrinking, or reshaping that part of the business. The current reading is $21M That compares with $13M in the prior-year period — up 61.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this ebit page, Stockcircle has Nature`s Sunshine Products's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $21M) with ownership activity and broader fundamentals.